Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...

Two decades ago, when two genetic mutations were discovered in Asia that gave scientists a better idea of how pain sensations traveled through the body and identified which part of the nervous system ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). The Boston-based Big Biotech’s sodium channel inhibitor VX-993 failed to outpace ...

Vertex has a solid cystic fibrosis portfolio that generates billions of dollars in annual earnings -- and that’s set to continue for the long term. The biotech, expanding into other treatment areas, ...